News from Cipla, Dr Reddy’s and Immunogen – People on the move
Cipla has appointed Subhanu Saxena its new CEO.
Previously he was the head of global product strategy and commercialisation business for Novartis.
Yusuf Hamied, chairman of Cipla said: “We are delighted to have found such a good match for Cipla in Subhanu. Cipla has a strong vision for the future. I am confident Subhanu will build on Cipla’s core values to deliver the next phase of growth, competitiveness and return on shareholder value.”
Dr. Reddy's Laboratories has named Umang Vohra executive VP and head of North American generics.
He was previously the Indian drugmaker’s CFO. Taking his place is current president and global head of quality Saumen Chakraborty.
Chakraborty returns to the role after serving as CFO between 2006 and 2008.
Charles Morris has joined ImmunoGen as executive VP and chief development officer.
In his new role will take charge of all product development activities.
Previously, he worked for Allos Therapeutics where he was executive BP and chief medical officer.
Daniel Junius, president and CEO said: “Charlie has extensive experience leading the strategic development and registration of novel oncology compounds – expertise essential to ImmunoGen with our advancing and expanding product pipeline.
“We are excited to have Charlie joining ImmunoGen at this important time in our transition to being a product development company.”
IntelliCell BioSciences has drafted Michael Hershman onto its board of directors.
Hershman is also a member of the board for the US Chamber of Commerce Foundation, and advises the Chamber on corporate compliance issues.
Chairman and CEO Steven Victor said: "His international experience and accomplishments will add a very significant capability to our board and our company. Mr. Hershman has long been recognized as one of the most influential business people worldwide and we are looking forward to working with him as we strengthen the IntelliCell executive management team with world class people."
Verastem has taken on Alison Lawton and Michael Kauffman as board members.
Lawton is currently senior VP and general manager of the Sanofi Biosurgery business unit, whilst Kauffman is the cofounding CEO of Karyopharm Therapeutics.
“Together, Ms. Lawton and Dr. Kauffman bring leadership in the clinical, regulatory and commercial aspects of the biopharmaceutical industry to Verastem at a transformative time in our development,” said Henri Termeer, Lead Director of Verastem.
Jean-Marc Pardonge will become president of Aptar Pharma’s prescription division.
He first joined the firm in 2000 as research and development (R&D) manager.
In a statement, the firm said: “Aptar Pharma’s prescription division will leverage Jean-Marc Pardonge’s in-depth knowledge of both the pharmaceutical market and the division’s customers to take full advantage of market opportunities for growth.”
